[Possible Pitfalls of Ipilimumab Therapy in XXXX  - a  Case Report].

@entity1 @entity2744 @entity320 @entity4386
BACKGROUND: @entity320 is a malignancy with one of the highest mortality rates. However, with the introduction of new drugs during the last decade, the prognosis of @entity1 began to improve. Ipilimumab is one of the first socalled modern drugs in @entity320 treatment. The therapy is often complicated by adverse effects which are referred as immunerelated adverse events due to its mechanism of action. CASE: We present a case of 68yearold @entity1 with @entity320 who underwent treatment with ipilimumab. The @entity1 encountered several adverse events during the treatment. Some of them are quite common (e.g. skin affections), others (e.g. @entity2744 ) are less frequent. CONCLUSION: This case study highlights the need for close observation not only during the actual treatment with ipilimumab, but also several weeks or months after the last dose. This case study also demonstrates further need of education of doctors who do not usually come in to contact with such @entity1 .Key word: @entity320 - ipilimumab - hypohysitis - @entity4386 The work was realized with the support PRVOUK 37/06.The authors declare they have no potential conflicts of interest concerning drugs, products, or   services used in the study.The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.Submitted: 30. 8. 2015Accepted: 20. 9. 2015.
